What question did this study set out to answer?

To determine whether phosphodiesterase type 5A inhibition with sildenafil reduces persistent pulmonary hypertension in patients following left ventricular unloading with an LVAD.

November 1, 2008Circulation Heart FailureOpen Access

PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support

View Full Paper

Ask AI

Bookmark

Authors

RTRyan J. TedfordHeart Failure & Transplant AHAnna R. HemnesVascular Medicine SRStuart D. RussellHeart Failure & Transplant

Discussion

Member takes

Implication

Open-label trial demonstrates sildenafil lowers pulmonary vascular resistance in LVAD recipients with persistent pulmonary hypertension, suggesting improved suitability for heart transplantation.

Key Points

To determine whether phosphodiesterase type 5A inhibition with sildenafil reduces persistent pulmonary hypertension in patients following left ventricular unloading with an LVAD.
Conducted an open-label controlled trial between 1999 and 2007 among 138 consecutive cardiac transplant candidates receiving LVAD therapy.
Identified 58 patients with normalized pulmonary capillary wedge pressure (<15 mm Hg) 1 to 2 weeks post-implantation who maintained elevated pulmonary vascular resistance (>3 Wood Units).
Administered oral sildenafil titrated to an average of 51.9 mg three times daily to 26 consecutive patients and compared outcomes against 32 untreated control patients at 12 to 15 weeks.
Average pulmonary vascular resistance in the sildenafil arm decreased from 5.87±1.93 to 2.96±0.92 Wood Units (P<0.001) compared with untreated control patients.
Mean pulmonary artery pressure in sildenafil-treated patients fell from 36.5±8.6 to 24.3±3.6 mm Hg (P<0.0001), significantly lower than the 32 untreated controls at follow-up.
Hemodynamic measurements of right ventricular function showed significant improvement in the sildenafil group relative to control patients.

Cite This Study

Tedford et al. (2008) studied this question.

synapsesocial.com/papers/6a09aacfc2775acaef511afc https://doi.org/10.1161/circheartfailure.108.796789

View Full Paper

Ask AI

Bookmark

Implication

Open-label trial demonstrates sildenafil lowers pulmonary vascular resistance in LVAD recipients with persistent pulmonary hypertension, suggesting improved suitability for heart transplantation.

PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support

Discussion

Member takes

Implication

Key Points

Cite This Study

PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider